We are live on ! Find out more
5VM

5AM Venture Management Portfolio holdings

AUM $360M
1-Year Est. Return 345.76%
This Fund
S&P 500
This Quarter Est. Return
+12.14%
1 Year Est. Return
+345.76%
3 Year Est. Return
+491.51%
5 Year Est. Return
+330.26%
10 Year Est. Return
–
AUM
$377M
AUM Growth
+$29.4M
Cap. Flow
+$9.81M
Cap. Flow %
2.6%
Top 10 Hldgs %
73.32%
Holding
28
New
2
Increased
4
Reduced
2
Closed
3

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$12.4M
2
MRUS
Merus
MRUS
+$12.2M
3
CLDX icon
Celldex Therapeutics
CLDX
+$5.5M
4
PHVS icon
Pharvaris
PHVS
+$4.25M
5
VRDN icon
Viridian Therapeutics
VRDN
+$2.79M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$13.7M
2
IRON icon
Disc Medicine
IRON
+$7.38M
3
ARVN icon
Arvinas
ARVN
+$6.28M
4
IMPL
Impel Pharmaceuticals Inc. Common Stock
IMPL
+$1.24M
5
MLTX icon
MoonLake Immunotherapeutics
MLTX
+$545K

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARVN icon
26
Arvinas
ARVN
$586M
– –
-320,000
Closed -$6.28M
CRNX icon
27
Crinetics Pharmaceuticals
CRNX
$8.91B
– –
-462,286
Closed -$13.7M
IMPL
28
DELISTED
Impel Pharmaceuticals Inc. Common Stock
IMPL
– –
-2,884,791
Closed -$1.24M
1
2

Similar funds

LSC
Logan Stone Capital Chicago, Illinois $360M AUM 9.71% 1-Year Est. Return
WIP
WealthCare Investment Partners Portsmouth, Rhode Island $360M AUM 19.98% 1-Year Est. Return
RA
RR Advisors Dallas, Texas $360M AUM 28.52% 1-Year Est. Return
SWM
SK Wealth Management Providence, Rhode Island $360M AUM 14.81% 1-Year Est. Return
NC
Naman Capital Sao Paulo, Brazil $360M AUM 27.43% 1-Year Est. Return
MCM
Monimus Capital Management Woodbridge, New Jersey $361M AUM 21.17% 1-Year Est. Return
KLWA
Kelly Lawrence W & Associates Pasadens, California $360M AUM 16.9% 1-Year Est. Return
PWC
PYA Waltman Capital Knoxville, Tennessee $361M AUM 9.49% 1-Year Est. Return

5AM Venture Management's Q4 2023 Portfolio in Review

As of Q4 2023, 5AM Venture Management held 28 positions worth $377M, up 8.5% from $348M the previous quarter. Its ten largest holdings account for 73% of the portfolio.

5AM Venture Management's Q4 2023 filing shows 2 new, 4 increased, 2 reduced and 3 closed positions. Its largest new stake was Biohaven: 399,972 shares worth $17.1M. The largest sale was Crinetics Pharmaceuticals, an estimated $13.7M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • 5AM Venture Management's largest Q4 2023 buy was Biohaven: 399,972 shares worth $17.1M.
  • 5AM Venture Management added most to Celldex Therapeutics in Q4 2023, an estimated $5.5M increase.
  • 5AM Venture Management's biggest Q4 2023 reduction was Disc Medicine, cutting an estimated $7.38M.
  • 5AM Venture Management fully exited Crinetics Pharmaceuticals in Q4 2023, selling an estimated $13.7M.
  • 5AM Venture Management's ten largest holdings make up 73% of its $377M portfolio in Q4 2023.
  • 5AM Venture Management opened 2 new positions and closed 3 in Q4 2023.
  • 5AM Venture Management's portfolio value rose 8.5% quarter-over-quarter to $377M.

Based on 5AM Venture Management's 13F filing for Q4 2023, filed 14 Feb 2024.